{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:6287"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:6287","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"An investigation into the effects of allosteric modulators of the human 5-Ht\\(_3\\)\\(_A\\) receptor","abstract":"The 5-Ht\\(_3\\)\\(_A\\) receptor is a cys-loop ligand gated ion channel re-emerging as an attractive target in irritable bowel syndrome (IBS), which currently affects 5-10% of the global population. At present, IBS therapies involve the complete blockade of the 5-Ht\\(_3\\)\\(_A\\) receptor by orthosteric antagonists, which leads to complications such as severe constipation and ischaemic colitis. Allosteric modulation could bypass such side effects, as receptor function relies upon the endogenous neurotransmitter to retain physiological control. Here, we investigate the structure and function of the 5-Ht\\(_3\\)\\(_A\\) receptor allosteric binding site by the identification of novel allosteric compounds and the generation of an α7/5-HT\\(_3\\)\\(_A\\) chimeric receptor. Intracellular calcium assays and competitive radioligand binding experiments indicated that the halogenated indole derivatives, 5-chloroindole (5-Cl) (Newman et al., 2013) and 5- (trifluoromethyl)indole (5-TFMI) are positive allosteric modulators (PAM) of the 5-Ht\\(_3\\)\\(_A\\) receptor; however 5-TFMI also displayed a degree of orthosteric binding. The structural analogues, 5-bromoindazole (5-BI) and 5-bromo-benzimidazole (5-BBI) exhibited contrasting effects, by potentiating and decreasing 5-HT-evoked responses, respectively. Further studies suggested some orthosteric binding by 5-BI and 5-BBI at high concentrations. The allosteric binding site for 5-Cl was previously located in the N-terminus of the mouse 5-Ht\\(_3\\)\\(_A\\) receptor. To identify the site in the human receptor, we attempted to construct a human chimeric α7V\\(_2\\)\\(_0\\)\\(_1\\)5-HT\\(_3\\)\\(_A\\) receptor to allow further investigation into this question. Our data suggest these halogenated indoles are allosteric compounds and, when studied in combination with the α7V\\(_2\\)\\(_0\\)\\(_1\\)5-HT\\(_3\\)\\(_A\\) chimera, could identify the required core structure of high affinity compounds needed for negative allosteric modulation in the treatment of IBS.","abstract_html":"The 5-Ht<span class=\"etd-inline-math\"><sub>3</sub></span><span class=\"etd-inline-math\"><sub>A</sub></span> receptor is a cys-loop ligand gated ion channel re-emerging as an attractive target in irritable bowel syndrome (IBS), which currently affects 5-10% of the global population. At present, IBS therapies involve the complete blockade of the 5-Ht<span class=\"etd-inline-math\"><sub>3</sub></span><span class=\"etd-inline-math\"><sub>A</sub></span> receptor by orthosteric antagonists, which leads to complications such as severe constipation and ischaemic colitis. Allosteric modulation could bypass such side effects, as receptor function relies upon the endogenous neurotransmitter to retain physiological control. Here, we investigate the structure and function of the 5-Ht<span class=\"etd-inline-math\"><sub>3</sub></span><span class=\"etd-inline-math\"><sub>A</sub></span> receptor allosteric binding site by the identification of novel allosteric compounds and the generation of an α7/5-HT<span class=\"etd-inline-math\"><sub>3</sub></span><span class=\"etd-inline-math\"><sub>A</sub></span> chimeric receptor. Intracellular calcium assays and competitive radioligand binding experiments indicated that the halogenated indole derivatives, 5-chloroindole (5-Cl) (Newman et al., 2013) and 5- (trifluoromethyl)indole (5-TFMI) are positive allosteric modulators (PAM) of the 5-Ht<span class=\"etd-inline-math\"><sub>3</sub></span><span class=\"etd-inline-math\"><sub>A</sub></span> receptor; however 5-TFMI also displayed a degree of orthosteric binding. The structural analogues, 5-bromoindazole (5-BI) and 5-bromo-benzimidazole (5-BBI) exhibited contrasting effects, by potentiating and decreasing 5-HT-evoked responses, respectively. Further studies suggested some orthosteric binding by 5-BI and 5-BBI at high concentrations. The allosteric binding site for 5-Cl was previously located in the N-terminus of the mouse 5-Ht<span class=\"etd-inline-math\"><sub>3</sub></span><span class=\"etd-inline-math\"><sub>A</sub></span> receptor. To identify the site in the human receptor, we attempted to construct a human chimeric α7V<span class=\"etd-inline-math\"><sub>2</sub></span><span class=\"etd-inline-math\"><sub>0</sub></span><span class=\"etd-inline-math\"><sub>1</sub></span>5-HT<span class=\"etd-inline-math\"><sub>3</sub></span><span class=\"etd-inline-math\"><sub>A</sub></span> receptor to allow further investigation into this question. Our data suggest these halogenated indoles are allosteric compounds and, when studied in combination with the α7V<span class=\"etd-inline-math\"><sub>2</sub></span><span class=\"etd-inline-math\"><sub>0</sub></span><span class=\"etd-inline-math\"><sub>1</sub></span>5-HT<span class=\"etd-inline-math\"><sub>3</sub></span><span class=\"etd-inline-math\"><sub>A</sub></span> chimera, could identify the required core structure of high affinity compounds needed for negative allosteric modulation in the treatment of IBS.","abstract_has_math":true,"creators":["Palandri, Josephine C."],"institution":"University of Birmingham","degree_name":"m_sc","degree_level":"m_sc","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015-12","date_published":"2015-12","updated_at":"2026-11-19T09:28:49Z","subjects":["RM Therapeutics. Pharmacology"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/6287/1/Palandri15MScbyRes.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A6287","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Palandri, Josephine C."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2015-12"]},{"key":"dc:date.issued","label":"Date","values":["2015-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","School of Clincal and Experimental Medicine, Department of Pharmacology and Therapeutics"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/6287/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["m_sc"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["m_sc"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RM Therapeutics. Pharmacology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/6287/1/Palandri15MScbyRes.pdf","http://etheses.bham.ac.uk//id/eprint/6287/8/Decl_IS_Palandri15MScbyRes.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The 5-Ht\\(_3\\)\\(_A\\) receptor is a cys-loop ligand gated ion channel re-emerging as an attractive target in irritable bowel syndrome (IBS), which currently affects 5-10% of the global population. At present, IBS therapies involve the complete blockade of the 5-Ht\\(_3\\)\\(_A\\) receptor by orthosteric antagonists, which leads to complications such as severe constipation and ischaemic colitis. Allosteric modulation could bypass such side effects, as receptor function relies upon the endogenous neurotransmitter to retain physiological control. Here, we investigate the structure and function of the 5-Ht\\(_3\\)\\(_A\\) receptor allosteric binding site by the identification of novel allosteric compounds and the generation of an α7/5-HT\\(_3\\)\\(_A\\) chimeric receptor. Intracellular calcium assays and competitive radioligand binding experiments indicated that the halogenated indole derivatives, 5-chloroindole (5-Cl) (Newman et al., 2013) and 5- (trifluoromethyl)indole (5-TFMI) are positive allosteric modulators (PAM) of the 5-Ht\\(_3\\)\\(_A\\) receptor; however 5-TFMI also displayed a degree of orthosteric binding. The structural analogues, 5-bromoindazole (5-BI) and 5-bromo-benzimidazole (5-BBI) exhibited contrasting effects, by potentiating and decreasing 5-HT-evoked responses, respectively. Further studies suggested some orthosteric binding by 5-BI and 5-BBI at high concentrations. The allosteric binding site for 5-Cl was previously located in the N-terminus of the mouse 5-Ht\\(_3\\)\\(_A\\) receptor. To identify the site in the human receptor, we attempted to construct a human chimeric α7V\\(_2\\)\\(_0\\)\\(_1\\)5-HT\\(_3\\)\\(_A\\) receptor to allow further investigation into this question. Our data suggest these halogenated indoles are allosteric compounds and, when studied in combination with the α7V\\(_2\\)\\(_0\\)\\(_1\\)5-HT\\(_3\\)\\(_A\\) chimera, could identify the required core structure of high affinity compounds needed for negative allosteric modulation in the treatment of IBS."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["An investigation into the effects of allosteric modulators of the human 5-Ht\\(_3\\)\\(_A\\) receptor"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Palandri, Josephine C."],"dc:date":["2015-12"],"dc:date.issued":["2015-12"],"dc:description.abstract":["The 5-Ht\\(_3\\)\\(_A\\) receptor is a cys-loop ligand gated ion channel re-emerging as an attractive target in irritable bowel syndrome (IBS), which currently affects 5-10% of the global population. At present, IBS therapies involve the complete blockade of the 5-Ht\\(_3\\)\\(_A\\) receptor by orthosteric antagonists, which leads to complications such as severe constipation and ischaemic colitis. Allosteric modulation could bypass such side effects, as receptor function relies upon the endogenous neurotransmitter to retain physiological control. Here, we investigate the structure and function of the 5-Ht\\(_3\\)\\(_A\\) receptor allosteric binding site by the identification of novel allosteric compounds and the generation of an α7/5-HT\\(_3\\)\\(_A\\) chimeric receptor. Intracellular calcium assays and competitive radioligand binding experiments indicated that the halogenated indole derivatives, 5-chloroindole (5-Cl) (Newman et al., 2013) and 5- (trifluoromethyl)indole (5-TFMI) are positive allosteric modulators (PAM) of the 5-Ht\\(_3\\)\\(_A\\) receptor; however 5-TFMI also displayed a degree of orthosteric binding. The structural analogues, 5-bromoindazole (5-BI) and 5-bromo-benzimidazole (5-BBI) exhibited contrasting effects, by potentiating and decreasing 5-HT-evoked responses, respectively. Further studies suggested some orthosteric binding by 5-BI and 5-BBI at high concentrations. The allosteric binding site for 5-Cl was previously located in the N-terminus of the mouse 5-Ht\\(_3\\)\\(_A\\) receptor. To identify the site in the human receptor, we attempted to construct a human chimeric α7V\\(_2\\)\\(_0\\)\\(_1\\)5-HT\\(_3\\)\\(_A\\) receptor to allow further investigation into this question. Our data suggest these halogenated indoles are allosteric compounds and, when studied in combination with the α7V\\(_2\\)\\(_0\\)\\(_1\\)5-HT\\(_3\\)\\(_A\\) chimera, could identify the required core structure of high affinity compounds needed for negative allosteric modulation in the treatment of IBS."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/6287/1/Palandri15MScbyRes.pdf","http://etheses.bham.ac.uk//id/eprint/6287/8/Decl_IS_Palandri15MScbyRes.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","School of Clincal and Experimental Medicine, Department of Pharmacology and Therapeutics"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/6287/"],"dc:subject":["RM Therapeutics. Pharmacology"],"dcterms:accessrights":["public","staffonly"],"dc:title":["An investigation into the effects of allosteric modulators of the human 5-Ht\\(_3\\)\\(_A\\) receptor"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["m_sc"],"dc:type.qualificationname":["m_sc"]},"updated_at":"2026-11-19T09:28:49Z"}